• Twitter
  • Facebook
  • Linkedin
  • Mail
GVN
COVID-19 Variants and Vaccines
  • Home
  • About
    • About
    • Mission
    • Letter from the President
    • Board of Directors
    • Senior Advisors
    • Scientific Leadership Board
    • Media Inquiries
    • GVN Team
    • Partners
    • Careers at GVN
  • GVN Members
    • GVN Academic Centers of Excellence & Affiliates
    • GVN Healthcare & Pharma Centers of Excellence Coalition
    • GVN Regional Headquarters
  • Activities
    • Research
      • GVN SARS-CoV-2 Response Effort Highlights
      • SARS-CoV-2 Task Force
      • Emerging Pathogens Discovery Network Working Group
      • Zika Virus Task Force
      • HTLV-1 Task Force
      • Chikungunya Task Force
      • Translational Medicine and Clinical Research
    • Training
      • The GVN – Abbott Pandemic Defense Postdoctoral Fellowship Program
      • GVN Drs. Yang Liu & Pan Zheng Academy Program
      • 7th Annual Short Course in Basic and Translational Virology
      • Online Course on Microbiomes and their Impact on Viral Infections
      • Short Course Alumni Database
      • Hepatitis In India
    • Advocacy
      • Initiatives
      • HTLV-1 Letter
  • Publications
    • 2021 Annual Report
    • GVN COVID-19 Perspectives
    • The Other Side of Virology: Beyond the COVID-19 Pandemic
    • GVN Weekly Brief
    • GVN Webinars
    • GVN Center/Member Publications
    • GVN Center and Member Spotlights
    • GVN Previous Publications
  • Events
    • GVN-Monaco COVID-19 Diagnostic Conference
    • GVN Annual Meetings
    • Robert C. Gallo Award
    • Zika Virus Meeting
  • News
    • Press Releases
    • GVN in the News
    • Media Inquiries
    • GVN Weekly Brief
    • Join the GVN Mailing List
  • SARS-CoV-2
    • GVN Variants and Vaccine Resource Portal
    • Dr. Christian Brechot Blog
    • GVN Center & Member Spotlight
    • GVN COVID-19 Webinar Series
    • GVN SARS-CoV-2 Perspectives
    • GVN in the News
    • Saliva Testing for COVID-19
  • Members Login
  • Search
  • Menu
  • Frequently Asked Questions
  • COVID-19 Variants
    • Alpha (B.1.1.7)
    • Beta (B.1.351)
    • Gamma (P.1)
    • Delta (B.1.617.2)
    • Omicron (B.1.1.529)
    • Variants of Interest
  • COVID-19 Vaccines
    • Vaccine Overview
    • Vaccine Development & Clinical Trials
    • Vaccine Safety
  • News & Publications

Front-Runner COVID-19 Vaccines

Pfizer-BioNTech

  • mRNA based vaccine by Expressing stabilized spike protein
  • Required 2 doses (3 weeks apart) and freezer storage at –70°C
  • Protective efficacy is 94%. A similar level of vaccine efficacy (94%) was observed for people older than 65.
  • The vaccine remains effective in a mass vaccination campaign in Israel.
  • Vaccination has resulted in the decrease in the rate of symptomatic COVID-19 by 94% and the rate of serious by 92%.
  • The company confirmed that the vaccine is effective against variants from the U.K. and South Africa.
  • In vitro study showed that the vaccine is slightly less protective against the variant from South Africa than original virus. Further study will be required for validation.

Moderna

  • Image by Marco Verch. License: https://creativecommons.org/licenses/by/2.0/

    mRNA based vaccine by expressing stabilized spike protein

  • Required 2 doses (4 weeks apart) and freezer storage at –4°C
  • Provides protection against severe COVID-19 (protective efficacy: 94.5%).
  • In a small clinical trial, the participants maintained a strong immune response after three months of vaccination.
  • The company confirmed that the vaccine is effective against variants from the U.K. and South Africa.
  • In vitro study showed that the vaccine is slightly less protective against the variant from South Africa than original virus. Further study will be required for validation.

Oxford-AstraZeneca

  • Adenovirus vectored vaccine
  • Required 2 doses and storage at 2-8°C
  • Protective efficacy was 82.4% (two dose vaccination with interval of 12 weeks).
  • Vaccine provides similar level of protection against the variant from the UK compared to original virus.
  • In South Africa, AstraZeneca vaccination was halted since clinical trials did not show protection against mild or moderate illness. However, scientists are reevaluating the data to reconsider the vaccination against more severe cases of COVID-19.
  • On-going clinical trials by a combination of Oxford-AstraZeneca and Sputnik V vaccines
  • On-going clinical trial: participation of 300 Children in UK

Gamaleya (Sputnik V)

  • Image by Marco Verch.
    License: https://creativecommons.org/licenses/by/2.0/

    A heterologous recombinant adenovirus based vaccine

  • Required prime and boost (3 weeks apart) and storage at 2-8°C
  • Induces strong humoral and cellular immune responses 
  • Vaccine efficacy was 91.6%
  • On-going clinical trials by a combination of Oxford-AstraZeneca and Sputnik V vaccines

Johnson & Johnson

  • Adenovirus vectored vaccine
  • Required a single dose and storage at 2-8°C
  • Clinical trials showed that 72% efficacy in the US and 57% efficacy in South Africa.
  • South Africa is considering using this vaccine. Although the vaccine provided 57% efficacy against moderate to severe COVID-19, it provided a better protection (85% efficacy) against severe disease after 28 days post-vaccination.
  • On-going phase 3 trial: use of two doses of vaccination

Novavax

  • Recombinant spike protein with nanoparticle based vaccine
  • Required two doses (3 weeks apart) and storage at 2-8°C
  • Vaccine provides similar level of protection against the variant from the UK compared to original virus.
  • Clinical trials showed that 89% efficacy in the UK and 60% efficacy in South Africa.

Sinovac and Sinopharm

  • Image by Rolly Reyna License: https://creativecommons.org/licenses/by/2.0/

    Inactivated vaccines

  • Required two doses and storage at 2-8°C
  • Efficacy of Sinovac from clinical trials was 91.25% in Turkey, 65.3% in Indonesia, and 50.4% in Brazil.
  • Efficacy of Sinopham was 79% (general) and 86% in EAU.

Ongoing Clinical Trials

Type of Vaccine
Company
In Use

Adenovirus Vectored

Johnson & Johnson

Phase III for two dose vaccination

mRNA based

Moderna

Phase I (2 doses, 4 weeks apart); variant B.1.355 vaccine

Nanoparticle based

Novavax

Phase III (2 doses, 3 weeks apart)

mRNA based

CureVac

Phase III (2 doses, four weeks apart)

Protein based

Vector Institute

Phase III (2 doses, 3 weeks apart)

Virus-like particle

Medicago

Phase III (2 doses, 3 weeks apart)

Protein-adjuvant based

Anhui Zhifei Longcom

Phase III (3 doses, 4 weeks apart)

DNA-based

Zydus Cadila

Phase III (3 doses, 4 weeks apart)

DNA-based

AnGes

Phase III (2 doses, 2 weeks apart)


Subunit

Biological E

Phase III (2 doses, 4 weeks apart)

DNA-based

Inovio

Phase II/III (2 doses, 4 weeks apart)

Subunit

Clover

Phase II/III (2 doses, 3 weeks apart)

Virus-like particle

SK Bioscience

Phase I/II (2 doses, 4 weeks apart)

Protein based

Sanofi

Phase II (2 doses, 3 weeks apart)

mRNA based

Sanofi

Phase I/II (2 doses, 3 weeks apart)

Clinical trial phases

Phase 1: Evaluation of safety and antibody production

Phase 2: Evaluation of safety and immunogenicity by including a placebo group

Phase 3: Verification of safety, and efficacy in a large population group

Frequently Asked Questions

Contact GVN

725 West Lombard St
Room S413
Baltimore, MD 21201
(410)-706-1966

Contact Us

Support GVN

Support

The Global Virus Network is a 501(C)3.

Join Our Mailing List

Subscribe
© Copyright - GVN - Enfold Theme by Kriesi
  • Twitter
  • Facebook
  • Linkedin
  • Mail
Scroll to top